NCT06862739RecruitingPhase 4
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- First submitted
- 19 Feb 2025
- Start date
- 30 Oct 2025
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- Nabiqasim Industries (Pvt) Ltd
- Diseases
- Type 2 diabetes
- NCT number
- NCT06862739
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 800
- From 30 Oct 2025 to the primary completion date, 30 Apr 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with Type-I diabetes
- Patients having diabetes for less than 06 months
- Patients with decompensated chronic liver disease (DCLD)
- Patients with end-stage heart failure (NYHA Class 4)
- Patients who are allergic to empagliflozin, linagliptin, or metformin
Lab values
- Patients with eGFR less than 30 ml
Age
- Patients with age less than 18
Other
- Patients on GLP-1 and GIP
- Patients who are pregnant or lactating females
- Patients who are not willing to consent
- Patients who are unable to give medical history
Who the study is looking for
- Patients of any gender
- Patients aged between 18-80 years
- Patients having HbA1c 8 % or above
- Patients diagnosed with type II diabetes (more than at least 06 months)
- Patients already on at least 02 or more anti-diabetic agents
- Patients not allergic to empagliflozin, linagliptin, or metformin
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faisalabad clinics Coordinator of this site? Confirm its status | Faisalabad | Pakistan | Recruiting |
| Aap ka Clinic Coordinator of this site? Confirm its status | Lahore | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.